A multicentre, multinational, randomised, double-blind, placebo-controlled, 3-arm, 24-week parallel-group study to evaluate the safety, tolerability and preliminary efficacy of ORY-2001 in patients with mild-moderate Alzheimer's Disease. ETHERAL Study

Trial Profile

A multicentre, multinational, randomised, double-blind, placebo-controlled, 3-arm, 24-week parallel-group study to evaluate the safety, tolerability and preliminary efficacy of ORY-2001 in patients with mild-moderate Alzheimer's Disease. ETHERAL Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs ORY 2001 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms ETHERAL
  • Sponsors Oryzon
  • Most Recent Events

    • 25 Jun 2018 According to an Oryzon media release, first patient has been enrolled in the UK, at St Pancras Clinical Research.
    • 29 May 2018 According to an Oryzon media release, study receives approval in the UK
    • 14 May 2018 According to an Oryzon media release, the French regulatory agency, and the Ethics Committee to start the trial in France just a few days ago. The first 3 patients have now been included in two hospitals from Barcelona. The study will be conducted in in UK once the corresponding approvals from the British regulatory authorities are obtained.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top